Corvus Pharmaceuticals News and Activities
Presence
Corvus Pharmaceuticals develops prescription medicines for cancer and immune diseases. Its pipeline includes small molecule and antibody therapies for hospitals, doctors, and patients.
Corvus Pharmaceuticals products and services overview:
- Oncology drugs
- Immunotherapy drugs
- Autoimmune treatments
- Small molecule therapies
- Antibody therapies
Revenue: ~$0 million
Employees: 32
Headquarters: Burlingame, United States (USA)
Corvus Pharmaceuticals is one of the...
Corvus Pharmaceuticals is a company listed under the stock ticker CRVS (US).
Executives
View the org chart displaying its 21 main executives
Most searched biographies at Corvus Pharmaceuticals
- Richard Miller, Chief Executive Officer and Chairman of the Board
- Scott Morrison, Director
- Linda Grais, Director
Popular executive movements at Corvus Pharmaceuticals
- Andrew Chan has joined the company as Director (posted on April 24 2026).
- David Moore has joined the company as Director (posted on October 3 2025).
Create your alert
to follow the executive moves at Corvus Pharmaceuticals.
Pharmaceuticals
Corvus Pharmaceuticals has 1,913 competitors including Sanofi (France), Eli Lilly (United States (USA)) and Moderna (United States (USA)).
Popular M&A news in Pharmaceuticals
- Contraline has just announced a $93 Million fundraising (posted on June 3 2026).
- Hims & Hers has acquired Eucalyptus (posted on June 2 2026).
- Apotex has filed its IPO. Its stock ticker will be TSX. (posted on June 2 2026).
Popular contacts in Pharmaceuticals
News
Press releases by Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma | Corvus Pharmaceuticals
- Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference | Corvus Pharmaceuticals
- Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results | Corvus Pharmaceuticals
- View more press releases Close
Social media about Corvus Pharmaceuticals
- Corvus Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
- Corvus Pharmaceuticals on LinkedIn, X (Twitter) & YouTube
